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attenuates diabetic cardiomyopathy in rats 
by alleviating fibrosis, reducing apoptosis 
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Abstract 
Background: Trimetazidine, as an anti‑ischemic and antioxidant agent, has been demonstrated to have many cardio‑
protective effects. However, whether early administration of trimetazidine has an effect on diabetic cardiomyopathy 
and the mechanisms underlying the effect have not yet been elucidated.
Methods: We established a type 2 DCM rat model by high‑fat diet and low‑dose streptozotocin. Rats were separated 
into different groups: control, diabetes, and diabetes + trimetazidine (n = 6, each). Cardiac autophagy, cardiac func‑
tions, and cardiomyocyte apoptosis were monitored.
Results: Rats with type 2 DCM showed severe insulin resistance, left ventricular dysfunction, increased cardiomyo‑
cyte apoptosis, and reduced cardiac autophagy. Collagen volume fraction (CVF) and perivascular collagen area/
luminal area (PVCA/LA) ratio were significantly higher in the diabetic group than the control group. We found that 
trimetazidine treatment ameliorated metabolic disturbance and insulin resistance, reduced cardiomyocyte apoptosis, 
and restored cardiac autophagy. CVF and PVCA/LA ratio were also lower in the diabetes + trimetazidine group than 
the diabetic group (CVF, 4.75 ± 0.52 % vs. 11.04 ± 1.67 %, p < 0.05; PVCA/LA, 8.37 ± 0.51 vs. 17.97 ± 2.66, p < 0.05). 
Furthermore, trimetazidine inhibited phosphorylation of ERK and P38 MAPK to reduce myocardial fibrosis. Inhibited 
phosphorylation of AMPK was restored and the interaction between Bcl‑2 and Beclin1 was enhanced in diabe‑
tes + trimetazidine group, resulting in the initiation of autophagy and alleviation of apoptosis.
Conclusions: Early administration of trimetazidine could ameliorate diabetic cardiomyopathy by inhibiting myocar‑
dial fibrosis and cardiomyocyte apoptosis and enhancing autophagy. Therefore, trimetazidine may be a good choice 
in the prevention of diabetic cardiomyopathy if applied at the early stage of diabetes.
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Background
Diabetic cardiomyopathy (DCM), which is a major car-
diac complication in diabetic patients, is one of the lead-
ing causes of increased morbidity and mortality in the 
diabetic population [1]. It is widely acknowledged that 
DCM is characterized by a set of structural and func-
tional abnormalities in the heart, including left ven-
tricular dysfunction, cardiomyocyte apoptosis, and 
myocardial fibrosis [2]. Recent studies have demonstrated 
that autophagy is also an important contributor to the 
development and the progression of DCM [3]. Despite 
lots of researches on the mechanisms of DCM have been 
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Trimetazidine, which is a first-line anti-anginal agent, 
selectively inhibits long-chain 3-ketoacyl coenzyme A 
thiolase (the last enzyme involved in β-oxidation) activ-
ity. The mechanism of action of trimetazidine can be 
attributed to its effect on energy metabolism. In addi-
tion to metabolic effects, trimetazidine has been shown 
to induce autophagy in skeletal muscle myotubes [4], 
inhibit pressure overload-induced cardiac fibrosis [5], 
and reduce smoking-induced apoptosis [6]. Although tri-
metazidine improves ejection fraction (EF) in patients of 
heart failure with or without ischaemic cardiomyopathy 
[7–11], the effect of early administration of trimetazidine 
on DCM and the mechanisms underlying the effect have 
not yet been elucidated.
Thus, we hypothesized that early administration of 
trimetazidine has an effect on DCM by inhibiting myo-
cardial fibrosis, reducing cardiomyocyte apoptosis and 
enhancing autophagic capacity. Thus, we established 
the type 2 DCM model and gave trimetazidine in  vivo 
to explore the effect of trimetazidine on DCM and the 
mechanism of this action.
Methods
Experiment design
The rat model of type 2 diabetes was established as 
described previously [12]. Eighteen male Sprague–Daw-
ley rats (120–140 g) were purchased from the experimen-
tal animal center of Shandong University of Traditional 
Chinese Medicine (Ji’nan, China). All rats were ran-
domly assigned to a control group (n  =  6) or diabetic 
group (n = 12). The diabetic groups were fed a high fat 
diet (Beijing HFK Bio-Technology, China) and the con-
trol group received normal chow. After 4 weeks, the rats 
with insulin resistance in the diabetic group were given a 
single intraperitoneal injection of streptozotocin (Sigma, 
St. Louis, MO; 27.5 mg/kg i.p. in 0.1 mol/L citrate buffer, 
pH 4.5). One week after streptozotocin administration, 
rats with plasma glucose levels >11.1 mmol/L were con-
sidered a diabetic rat model. The diabetic group (n = 12) 
was redivided into two groups: a diabetes group (n = 6) 
and a diabetes + trimetazidine group (n = 6). The diabe-
tes +  trimetazidine group was given a dose (30 mg kg–1   
day–1) of trimetazidine (Servier, France) by gavage for 
8 weeks. Then rats were sacrificed. The heart was excised 
and weighed. All animals received humane care and all 
experimental procedures were performed in accordance 
with animal protocols approved by the Shandong Univer-
sity Animal Care Committee.
Glucose and insulin tolerance
An intraperitoneal glucose tolerance test (IPGTT) was 
carried out to evaluate glucose after rats fasted for 12 h 
and then injected glucose (1  g/kg) intraperitoneally. 
Blood glucose level was evaluated at 0, 15, 30, 60, and 
120  min postinjection. An intraperitoneal insulin toler-
ance test (IPITT) was performed to assess insulin tol-
erance after rats fasted for 4  h and then administered 
insulin (1  unit/kg) intraperitoneally. Blood glucose level 
was measured as described above. Blood samples were 
collected from the tail vein and plasma glucose was 
measured with a one-touch glucometer (Life Scan, Mil-
pitas, CA). The mean area under the receiver operating 
characteristic curve (AUC) was calculated for glucose.
Blood analyses
After rats fasted overnight, blood samples were obtained 
from the jugular vein. Total cholesterol, triglycerides, 
fasting blood glucose, HDL-c, and LDL-c were analyzed 
with use of the Bayer 1650 blood chemistry analyzer 
(Bayer, Tarrytown, NY). Fasting insulin was measured by 
enzyme-linked immunosorbent assay. Insulin sensitivity 
index (ISI) was calculated using the following formula: 
ISI = ln [([fasting blood glucose] × [fasting insulin])−1].
Measurement of blood pressure
Heart rate, systolic blood pressure, diastolic blood pres-
sure, and mean arterial pressure were measured with a 
noninvasive tail-cuff system (Softron BP-98A; Softron, 
Tokyo, Japan) as described previously [13].
Hemodynamic examination
At the end of the experiments, rats under deep anesthesia 
underwent hemodynamic measurement. A catheter was 
inserted from the right common carotid artery into the 
left ventricle. Left ventricular (LV) end diastolic pressure 
was measured.
Histology and morphometric analysis
LV tissues were fixed in 4  % neutral formaldehyde and 
embedded in paraffin, and 4  μm-thick sections were 
produced. The sections were stained with HE, Masson-
Trichrome, and Picrosirius red. Collagen volume fraction 
(CVF) and perivascular area/luminal area (PVCA/LA) 
ratio were obtained by quantitative morphometry with 
automated image analysis (Image-Pro Plus, Version 5.0; 
Media Cybernatics, Houston, TX).
Immunohistochemical staining
Paraffin-embedded tissues were deparaffinized and sec-
tions were pretreated by microwaving them for 15  min 
and were incubated with primary polyclonal anti–col-
lagen I, and anti–collagen III (Abcam, Cambridge, 
MA) overnight at 4  °C and incubated with horseradish 
peroxidase-labeled secondary antibody for 1  h at 37  °C. 
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Negative controls were omission of the primary antibody. 
Finally, the results were viewed under a confocal FV 1000 
SPD laser scanning microscope (Olympus, Japan).
TUNEL assay
TUNEL (terminal deoxynucleotidyl transferase dUTP 
nick end labeling) detection of apoptotic cells in the 
hearts was carried out using the ApopTag Peroxidase 
In Situ Apoptosis Detection Kit (S7101, Chemicon, Bill-
erica, MA, USA). Images of the processed tissues were 
captured using a confocal FV 1000 SPD laser scanning 
microscope (Olympus, Japan).
Western blot analysis
Proteins were extracted from hearts, separated by SDS-
PAGE and transferred to polyvinylidene difluoride mem-
brane. The membranes were incubated with a 1:1000 
dilution of antibodies for p-AMPK, t-AMPK, Beclin 1, 
Caspase 3, PARP, Bcl-2, p-ERK, t-ERK, p-P38, t-P38, 
p-JNK, t-JNK, p-PI3  K, t-PI3K, p-AKT, t-AKT, mTOR, 
t-mTOR (Cell Signaling Technology, Danves MA, 
USA), a 1:1000 dilution antibodies for ATG5 and ATG7 
(Abcam, Cambridge, MA), and an antibody for Bcl-2 
(Biolegend, San Diego, CA) and then 1:10,000 horserad-
ish peroxidase-conjugated secondary antibody. Immu-
noreactive bands were visualized by use of an enhanced 
chemiluminescence reagent. Densitometry involved use 
of photoshop.
Coimmunoprecipitation assay
Proteins were extracted from hearts and then whole 
lysate was precleared with protein A/G sepharose beads 
(Santa Cruz) at 4 °C for 60 min. The cleared supernatant 
was incubated overnight at 4 °C with the indicated anti-
bodies, followed by incubation for 2 h at 4  °C with pro-
tein A/G sepharose beads. Finally, the beads were washed 
five times, eluted by boiling in sample buffer for SDS-
PAGE, and further immunoblot analysis was conducted 
with the indicated antibodies.
Statistical analysis
Values are presented as mean ± SEM. SPSS 16.0 (SPSS, 
Chicago, IL) was used for statistical analysis. Differences 
between experimental groups were determined by one-
way ANOVA or Student’s t test. p < 0.05 was considered 
statistically significant.
Results
Generation of type 2 DCM rat model
General characteristics of diabetic rats
At the end of the experiment, our results found that 
water intake, food intake, urine volume, and heart weight 
were significantly higher in the diabetic group than the 
control group. There was no difference in blood pressure 
between the three groups (Table 1).
Total cholesterol, triglycerides, fasting blood glucose, HDL‑c 
and LDL‑c
After 4  weeks of a high fat diet, there was little differ-
ence in total cholesterol, triglyceride, HDL-c and LDL-c 
levels between the diabetic and control groups (Fig.  1a, 
b, f, g). Serum fasting blood glucose and fasting insulin 
were significantly higher in the diabetic group than in 
the control group (fasting blood glucose, 8.93  ±  0.69 
vs. 5.61  ±  0.26  mmol/L, p  <  0.05; and fasting insulin, 
1.99 ± 0.97 vs. 1.05 ± 0.22 mU/L, p < 0.05, respectively) 
(Fig.  1c, d). ISI decreased significantly in the diabetic 
group (−2.81 ± 0.07 vs. −1.72 ± 0.21, p < 0.05) (Fig. 1e).
One week after streptozotocin injection (week 5), 
fasting blood glucose, triglycerides, and fasting insulin 
were significantly higher in the diabetic group than in 
the control group (fasting blood glucose, 15.20 ±  2.82 
Table 1 Animal characteristics at the end of experiment, according to study group (n = 5–6 per group)
Values are mean ± SEM. bpm, beats per minute
 *p < 0.05 compared with control group; and **p < 0.05 compared with diabetes group
Characteristic Control Diabetes mellitus Diabetes mellitus  
+ trimetazidine
Body weight (g) 434.17 ± 8.60 470.17 ± 27.874 433.67 ± 7.893
Heart weight (mg) 1096.00 ± 35.86 1463.33 ± 37.83* 1293.86 ± 47.94**
Water intake (mL/day) 28.20 ± 3.455 153.83 ± 10.329* 147.00 ± 10.440
Food intake (g/day) 14.44 ± 0.423 29.95 ± 1.090* 29.00 ± 1.163
Urine volume (mL/day) 22.60 ± 2.502 126.33 ± 7.766* 129.00 ± 10.416
Systolic blood pressure (mm Hg) 123.40 ± 4.490 120.67 ± 3.964 116.40 ± 5.609
Diastolic blood pressure (mm Hg) 89.00 ± 4.025 77.17 ± 4.888 84.20 ± 2.354
Mean pressure (mm Hg) 103.80 ± 5.229 90.33 ± 5.245 94.80 ± 3.089
Heart rate (bpm) 454.20 ± 15.714 491.67 ± 13.601 343.20 ± 14.235**
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Fig. 1 Changes in metabolic indices in rats in the control, diabetes mellitus (DM), and diabetes mellitus + trimetazidine (DM + TMZ) groups 
(n = 5–6 per group). Changes in levels of total cholesterol (TC) (a), triglyceride (TG) (b), fasting blood glucose (FBG) (c), fasting insulin (FINS) (d), 
insulin sensitive index (ISI) (e), HDL‑c (f) and LDL‑c (g) are shown. Values are mean ± SEM. *p < 0.05 compared with control group; #p < 0.05 com‑
pared with diabetes group and &p < 0.05 compared with control group
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vs. 5.35  ±  0.23  mmol/L, p  <  0.05; triglycerides, 
7.55 ±  1.54 vs. 0.48 ±  0.18  mmol/L; and fasting insu-
lin, 3.88 ± 0.56 vs. 1.37 ± 0.13 mU/L, p < 0.05, respec-
tively), and ISI and HDL-c were lower in the diabetic 
group (ISI, −3.91  ±  0.22 vs. −1.98  ±  0.08, p  <  0.05; 
and HDL-c, 0.53 ± 0.11 vs. 0.97 ± 0.01 mmol/L, respec-
tively) (Fig. 1b–f ). At the end of the experiment, serum 
total cholesterol, triglycerides, fasting blood glucose, 
fasting insulin and LDL-c were significantly higher in 
the diabetic group than in the control group (total cho-
lesterol, 5.72 ± 0.51 vs. 1.63 ± 0.13 mmol/L; triglycer-
ides, 7.55 ± 0.92 vs. 0.71 ± 0.11 mmol/L; fasting blood 
glucose, 25.07  ±  1.21 vs. 5.75  ±  0.30  mmol/L; fasting 
insulin, 7.20 ± 0.51 vs. 0.76 ± 0.13 mU/L, p < 0.05; and 
LDL-c, 0.66 ± 0.1 vs. 0.3 ± 0.03 mmol/L respectively). 
ISI and HDL-c decreased significantly in the diabetic 
group (ISI, −5.19 ± 0.19 vs. −1.46 ± 0.15, p < 0.05; and 
HDL-c, 0.33  ±  0.03 vs. 0.96  ±  0.17  mmol/L, respec-
tively). These findings showed the presence of metabolic 
disturbance and insulin resistance in the diabetic group.
Glucose and insulin tolerance
After a 4-week high fat diet, IPGTT and IPITT con-
firmed the presence of insulin resistance. At week 4, 
IPGTT revealed that blood glucose levels in the diabetic 
group were significantly higher at 0 and 30 min than at 
baseline (Fig. 2A1). The AUC across the time for glucose 
level was significantly higher at week 4 than at baseline 
(29.15  ±  0.84 vs. 32.93  ±  2.02,respectively; p  <  0.05, 
Fig.  2A2). Similarly, IPITT revealed impaired insulin 
sensitivity (Fig.  2A3, A4). These data showed that insu-
lin resistance appeared in the diabetic group after 4-week 
high fat diet. At the end of the experiment, the levels of 
blood glucose and AUC on both IPGTT and IPITT in the 
diabetic group were significantly higher than in the con-
trol group (Fig. 2B1–B4).
Pathology characteristics
At the end of the experiment, the ratio of heart weight 
to body weight was higher in the diabetic group than in 
the control group (3.39 ± 0.07 vs. 2.51 ± 0.05, p < 0.05, 
Fig. 3b). Meanwhile, the diabetic group revealed cardiac 
fibrosis, with destroyed and irregular collagen network 
structure in the interstitial and perivascular area. The 
diabetic group also showed significantly higher CVF 
(11.04 ± 1.67 % vs. 1.56 ± 0.24 %, p < 0.05, Fig. 3d) and 
PVCA/LA ratio (17.97 ±  2.66 vs. 2.91 ±  0.69, p < 0.05, 
Fig. 3e) compared with the control group.
Collagen I and III
Immunohistochemistry showed that the deposition of 
collagen I and III content was significantly higher in the 
diabetic group than in the control group (Fig. 4).
Apoptosis
TUNEL staining demonstrated that TUNEL-positive 
cells were seldom identified in the control group, but 
numerous TUNEL-positive cells were observed in the 
diabetic group (Fig.  5a). Consistently, western analysis 
showed a significant increase in cleavage of Caspase-3 
and Parp in the diabetic group (Fig. 6b).
Autophagy
The diabetic group revealed lower light chain 3 II (LC3-
II) protein levels compared with the control (Fig.  5c), 
indicating a reduction in cardiac autophagy. Meanwhile, 
ATG5 and ATG7 (autophagy indicators) were signifi-
cantly lower in the diabetic group than in the control 
group (Fig. 5d).
LV dysfunction assessed by catheterization
At the end of the experiment, LV end diastolic pressure 
was measured by cardiac catheterization. Diabetic rats 
showed higher LV pressure compared with the control 
(Fig. 6a). Thus, diastolic dysfunction developed and pro-
gressed during type 2 DCM.
PI3 K/AKT, MAPK and AMPK/Beclin1‑Bcl2 pathways
The levels of phosphorylated PI3 K, AKT and AMPK in 
diabetic group were significantly lower than in the control 
group (Figs.  7a, 8a). However, phosphorylated ERK, P38 
and JNK were significantly elevated in the diabetic group. 
Meanwhile, enhanced interaction between Bcl-2 and Bec-
lin1 was observed in the diabetic group (Figs. 7b, 8b).
Trimetazidine reverses type 2 DCM
Trimetazidine ameliorated metabolism
At the end of the experiment, heart rate and heart weight 
were decreased in the diabetic group with trimetazidine 
treatment (Table 1). Total cholesterol, triglyceride, fasting 
blood glucose, and fasting insulin were significantly lower 
in the trimetazidine group than in the diabetic group 
(total cholesterol, 2.86  ±  0.53 vs. 5.72  ±  0.51  mmol/L; 
triglycerides, 2.90 ±  0.78 vs. 7.53 ±  0.92  mmol/L; fast-
ing blood glucose, 15.33 ± 4.27 vs. 25.07 ± 1.21 mmol/L; 
fasting insulin, 3.37 ± 0.08 vs. 7.20 ± 0.51 mU/L, p < 0.05, 
respectively); the ISI and HDL-c were significantly 
increased in the trimetazidine group (ISI, −3.60 ±  0.85 
vs. −5.19  ±  0.19, p  <  0.05; HDL-c, 0.85  ±  0.07 vs. 
0.33 ± 0.03 mmol/L, p < 0.05, respectively). These find-
ings suggest that trimetazidine ameliorated metabolic 
disturbance and insulin resistance.
Trimetazidine improved glucose tolerance and insulin 
sensitivity
After the trimetazidine treatment, the IPGTT and IPITT 
revealed that levels of blood glucose in the trimetazidine 
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group were significantly lower than those of the diabetic 
group (Fig.  2B1, B3). The trimetazidine group showed 
lower mean AUC on both IPGTT and IPITT than the 
diabetic group (Fig. 2B2, B4).
Trimetazidine reversed myocardial remodeling and reduced 
the deposition of collagen I and III content
After the trimetazidine treatment, the ratio of heart 
weight to body weight was reduced (2.88  ±  0.09 
Fig. 2 Blood glucose in rats that underwent an intraperitoneal glucose tolerance test (IPGTT) or intraperitoneal insulin tolerance test (IPITT). a show 
blood glucose levels at baseline and after 4 weeks of high fat (HF) diet; while b compare blood glucose in rats in the control, diabetes mellitus (DM), 
and diabetes mellitus + trimetazidine (DM + TMZ) groups (n = 5–6 per group) at the end of the experiment. Values are mean ± SEM; n = 5–6 per 
group. *p < 0.05 compared with baseline (a) or control group (b); #p < 0.05 compared with diabetes group and &p < 0.05 compared with control 
group
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vs. 3.39  ±  0.07, p  <  0.05, Fig.  3b). The trimetazi-
dine group also showed lower CVF (4.75  ±  0.52  % vs. 
11.04 ±  1.67  %, p  <  0.05, Fig.  3d) and PVCA/LA ratio 
(8.37 ± 0.51 vs. 17.97 ± 2.66, p < 0.05, Fig. 3e) compared 
with the diabetic group. The deposition of collagen I and 
III content was significantly lower in the trimetazidine 
group than in the diabetic group after the trimetazidine 
treatment (Fig. 4).
Fig. 3 Pathological features of diabetic cardiomyopathy. a Cardiac hypertrophy in diabetic rats. Comparison of heart size (A1) (scale bar 2 mm), 
representative cross sections of hearts at the papillary muscle level (A2) (scale bar 2 mm), and longitudinal sections (A3) and transverse sections (A4) 
of left ventricle stained with hematoxylin and eosin (H&E; scale bar 50 μm) in rats in the control, diabetes mellitus (DM), and diabetes mellitus + tri‑
metazidine (DM + TMZ) groups (n = 5–6 per group). b Ratio of heart weight to body weight in rats in the control, DM, and DM + TMZ groups. c 
Cardiac fibrosis in diabetic rats. Interstitial fibrosis as shown by Masson‑Trichrome staining [collagen is green and myocardium red; scale bar 50 μm 
(C1)] and Picrosirius red staining (collagen fibers stained bright red; bright‑field (C2) and dark‑field (C3); scale bar 100 μm). Perivascular fibrosis as 
shown by Masson‑Trichrome staining (C4) (scale bar 100 μm) and Picrosirius red staining [bright‑field (C5) and dark‑field (C6); scale bar 100 μm]. 
d Comparison of collagen volume fraction (CVF) in rats in the control, DM, and DM + TMZ groups. e Comparison of perivascular collagen area/
luminal area (PVCA/LA) ratio in rats in the control, DM, and DM + TMZ groups. Values are mean ± SEM. *p < 0.05 compared with control group; and  
#p < 0.05 compared with diabetes group
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Trimetazidine restored autophagy and protected 
against cardiac apoptosis
TUNEL staining demonstrated that TUNEL-positive 
cells were significantly lower in the trimetazidine group 
than in the diabetic group (Fig. 5a). A significant decrease 
in cleavage of Caspase-3 and Parp were observed in the 
trimetazidine group (Fig.  5b). After the trimetazidine 
treatment, LC3-II, ATG5, and ATG7 were increased 
(Fig. 5c, d). These data suggest that trimetazidine restored 
autophagy and protected against cardiac apoptosis.
Trimetazidine improved cardiac function
After the treatment, LV end diastolic pressure was signif-
icantly lower in the trimetazidine group than in the dia-
betic group (Fig. 6a), which confirmed the benefit effect 
of trimetazidine on improving LV diastolic dysfunction.
Trimetazidine regulated PI3 K/AKT, MAPK and AMPK/
Beclin1‑Bcl2 pathways
After the treatment, trimetazidine enhanced PI3 K, AKT, 
JNK and AMPK activity and disrupted the complex of 
Bcl-2 and Beclin1 in the trimetazidine group compared 
with diabetic group (Figs.  7, 8). However, trimetazidine 
inhibited ERK and P38 MAPK activity in the trimetazi-
dine group compared with diabetic group (Fig. 7b).
Discussion
In our present study, we found that early administration 
of trimetazidine could ameliorate diabetic cardiomyo-
pathy. We showed this cardioprotective effect of tri-
metazidine was associated with decreased myocardial 
fibrosis, reduced cardiomyocyte apoptosis, and enhanced 
autophagic capacity. We demonstrated that trimetazidine 
Fig. 4 Collagen I and collagen III increased in rats with type 2 diabetes (DM), but decreased in rats with type 2 diabetes given trimetazidine 
(DM + TMZ). a, b and c show representative immunohistochemical staining of collagen I and III (scale bar 50 μm); semiquantification of collagen I 
staining; and semiquantification of collagen III staining, respectively
Page 9 of 12Zhang et al. J Transl Med  (2016) 14:109 
alleviated myocardial fibrosis by modulating MAPK 
pathway. In addition, trimetazidine restored autophagy 
and protected against cardiac apoptosis mainly by acti-
vating AMPK and dissociating Beclin1 and Bcl-2. Thus, 
early administration of trimetazidine could be a good 
choice in the prevention of diabetic cardiomyopathy if 
applied at the very early stage of diabetes.
Diabetic cardiomyopathy, independent of coronary 
artery disease and hypertension, is defined as left ven-
tricular dysfunction [14], and it is well established as 
one of the major causes of heart failure in diabetic 
patients. Since diabetic cardiomyopathy begins with a 
latent period clinically, treatment is often delayed and 
overlooked, resulting in poor prognosis. Thus, attention 
Fig. 5 Autophagy and cardiac apoptosis in rats in the control, diabetes mellitus (DM), and diabetes + trimetazidine (DM + TMZ) groups. a Repre‑
sentative images and analysis of the TUNEL assay (scale bar 20 μm). b Representative western blot bands and analysis of C‑Caspase 3/β‑actin and 
C‑PARP/β‑actin. c Representative western blot bands and analysis of LC3‑II/LC3‑I. d Representative western blot bands and analysis of ATG5/β‑actin 
and ATG7/β‑actin. Data are mean ± SEM. ATG, autophagy [protein]. C‑PARP, C–poly (ADP‑ribose) polymerase. LC3, light chain 3 [protein]. TUNEL, 
terminal deoxynucleotidyl transferase dUTP nick end labeling. *p < 0.05 compared with control group; and #p < 0.05 compared with diabetes group
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must be focused on the prevention of the disease. There-
fore, we treated the rats with trimetazidine at the early 
stage of diabetes. We found that trimetazidine reversed 
myocardial remodeling and improved LV diastolic dys-
function. Therefore, we can conclude that early admin-
istration of trimetazidine could ameliorate diabetic 
cardiomyopathy.
Insulin resistance plays a causal role in physiopathology, 
appearance and nosogenesis of metabolic disorder in vivo 
[15]. It increases the risk of cardiovascular damage in dia-
betes patients [16] and is one of the important causes in 
the development of DCM [12]. After early administra-
tion of trimetazidine for 8  weeks, insulin resistance was 
ameliorated in our study. One of the mechanisms that 
trimetazidine ameliorated the insulin-resistant states pos-
sibly via restoring the blunted insulin signaling pathway-
PI3 K/AKT. PI3 K/AKT, which is a key component in the 
signal transduction of insulin and plays a casual role in 
glucose and lipid metabolism [17], could promote GLUT4 
translocation to the sarcolemma [18]. Therefore, we 
explored the changes in the PI3 K/AKT pathway. In our 
Fig. 6 Left ventricular diastolic function in rats in the control, diabe‑
tes mellitus (DM), and diabetes mellitus + trimetazidine (DM + TMZ) 
groups at the end of the experiments. a shows pressure curves 
during cardiac catheterization, while b indicates left ventricular end 
diastolic pressure (LVEDP). Data are mean ± SEM; n = 5–6 per group. 
*p < 0.05 compared with control group; and #p < 0.05 compared with 
diabetes group
Fig. 7 PI3 K/AKT and MAPK pathways in the heart of rats in the control, diabetes mellitus (DM), and diabetes mellitus + trimetazidine (DM + TMZ) 
groups. a Representative western blot bands of p‑PI3 K, t‑PI3K, p‑AKT, t‑AKT, mTOR and t‑mTOR. b Representative Western blot bands of p‑ERR, 
t‑ERK, p‑P38, t‑P38, and p‑JNK, t‑JNK. c Representative western blot analysis of p‑PI3 K/t‑PI3K, p‑AKT/t‑AKT and mTOR/t‑mTOR. d Representative 
western blot analysis of p‑ERK/t‑ERK, p‑P38/t‑P38, and p‑JNK/t‑JNK
Page 11 of 12Zhang et al. J Transl Med  (2016) 14:109 
experiments, we found that the phosphorylation of PI3 K 
and AKT were decreased in type 2 diabetes rats model 
and trimetazidine restored PI3  K/AKT pathway. More 
recently, activation of AMPK has also been shown to trig-
ger the translocation of GLUT4 [19]. Thus, AMPK was 
also explored in our study. We found AMPK was inhibited 
in an insulin-resistant state and unregulated after admin-
istration of trimetazidine in our study. Therefore, tri-
metazidine ameliorated the insulin-resistant states mainly 
by activating PI3 K/AKT and AMPK pathways.
A major player in the pathophysiology of DCM is 
myocardial fibrosis. Myocardial fibrosis is characterized 
by excessive deposition of collagen I and III [20]. In this 
study, diabetic rats showed prominent collagen accu-
mulation in interstitial and perivascular areas on Mas-
son trichrome and Picrosirius red staining. Treatment 
of trimetazidine reduced the aberrant interstitial and 
perivascular collagen accumulation, as well as total col-
lagen content. Previous studies have shown that activated 
MAPK plays an essential role in cardiac fibrosis [12, 21]. 
Therefore, we explored the changes in the MAPK path-
way. We found a generalized decrease in phosphorylation 
of ERK and P38 MAPK, suggesting the improvements in 
cardiac fibrosis were mainly attributed to the decreased 
activation of ERK and P38 MAPK.
In contrast to its adaptive nature in type 1 diabetes, in 
most HFD-induced type 2 diabetic models the inhibited 
cardiac autophagy appears to be maladaptive, and thus 
strategies to enhancing autophagy may be cardiopro-
tective [22–24]. An increase in cardiac apoptotic cell 
death has also been demonstrated as a major event in 
the development of DCM [25, 26]. Therefore, autophagy 
and apoptosis were observed in our study. Inhibition 
of cardiac autophagy along with enhanced cardiomyo-
cyte apoptosis were found in the insulin-resistant states. 
Trimetazidine therapy restored cardiac autophagic 
activities and protected against apoptosis. Inhibition of 
AMPK enhances the interaction between Bcl-2 and Bec-
lin1 in type 1 diabetic mice, resulting in the alleviation of 
autophagy and the initiation of apoptosis [27]. Therefore, 
we explored the changes of AMPK and Bcl-2-Beclin1 
complex in the insulin-resistance states. Our study found 
that not only AMPK activity was significantly inhibited 
but also the interaction between Bcl-2 and Beclin1 was 
enhanced in our type 2 diabetes rats model. However, 
trimetazidine restored AMPK activity and dissociated 
the interaction between Bcl-2 and Beclin1. Combined 
with previous studies, trimetazidine restored autophagy 
and protected against cardiac apoptosis mainly by acti-
vating AMPK and dissociating Beclin1 and Bcl-2.
Conclusion
Early administration of trimetazidine could amelio-
rate diabetic cardiomyopathy by inhibiting myocardial 
Fig. 8 AMP‑activated protein kinase (AMPK) phosphorylation and the interaction between the B cell lymphoma 2 (Bcl‑2) and Beclin 1 proteins in 
the heart of rats in the control, diabetes mellitus (DM), and diabetes mellitus + trimetazidine (DM + TMZ) groups. a shows a western blot analysis 
of phosphorylated AMPK (p‑AMPK)/total AMPK (t‑AMPK), while b shows coimmunoprecipitation analysis of combination of the B‑cell lymphoma 
2 (Bcl‑2) protein and the protein Beclin 1. Data are mean ± SEM; AMP, adenosine monophosphate. *p < 0.05 compared with control group; and 
#p < 0.05 compared with diabetes group
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fibrosis, reducing cardiomyocyte apoptosis, and enhanc-
ing autophagy. Therefore, trimetazidine may be a good 
choice in the prevention of diabetic cardiomyopathy if 
applied at the very early stage of diabetes.
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